II. assessment of dyslipidemias

Slides:



Advertisements
Similar presentations
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Advertisements

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Volume 68, Pages S46-S52 (August 2005)
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know  Siddharth Singh, MD, Kymberly D. Watt,
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Volume 148, Issue 4, Pages (April 2015)
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Dyslipidemia in chronic kidney disease: Causes and consequences
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F
American Journal of Kidney Diseases 
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Peritoneal dialysis American Journal of Kidney Diseases
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Hypertension in the hemodialysis patient and the “lag phenomenon”: insights into pathophysiology and clinical management  Uday M Khosla, MD, Richard J.
Culture-negative peritoneal dialysis peritonitis associated with pancreaticoduodenocystotomy leak of a pancreas transplant  Lourdes T Terrado, MD, William.
Kostas C. Siamopoulos, MD, FRSH, Chariklia Gouva, MD, Konstantinos P
The US Renal Data System “Pie Chart of Death”
Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles  Jan.
Culture-negative peritoneal dialysis peritonitis associated with pancreaticoduodenocystotomy leak of a pancreas transplant  Lourdes T Terrado, MD, William.
James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D. 
Susumu Takahashi, Kazuyoshi Okada, Mitsuru Yanai  Kidney International 
I. Introduction American Journal of Kidney Diseases
If triglycerides matter, why do they matter?
Meeting the challenges of the new K/DOQI guidelines
Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles  Jan.
Erratum Regarding “Phosphate Removal With Several Thrice-Weekly Dialysis Methods in Overweight Hemodialysis Patients” [Am J Kidney Dis 2009; 54: ] 
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns.
Geriatrics American Journal of Kidney Diseases
Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson 
On Statin Treatment to Prevent Sepsis in Dialysis Patients
This Month in AJKD American Journal of Kidney Diseases
Hypertension in the hemodialysis patient and the “lag phenomenon”: insights into pathophysiology and clinical management  Uday M Khosla, MD, Richard J.
American Journal of Kidney Diseases
Volume 68, Pages S46-S52 (August 2005)
Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study  Eric D.
Acute myocardial infarction in patients with end-stage renal disease
Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,
American Journal of Kidney Diseases
The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis  Alexander S. Goldfarb-Rumyantzev, MD, PhD,
Manish M. Tanna, MD, Edward F. Vonesh, PhD, Stephen M. Korbet, MD 
Non–high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease  Yoshiki Nishizawa,
Volume 67, Issue 4, Pages (April 2005)
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients  Florian Kronenberg, Arno Lingenhel, Ulrich Neyer, Karl Lhotta, Paul König, Martin.
Characteristics of included studies
Multidrug-Resistant Organisms Within the Dialysis Population: A Potentially Preventable Perfect Storm  David P. Calfee, MD, MS  American Journal of Kidney.
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease  Dean G. Karalis, MD  Mayo Clinic Proceedings 
The ACCORD Study Group. NEJM 2010; Epub March 14
The Use of Vaccines in Adult Patients With Renal Disease
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Anil K. Saxena, MD, B.R. Panhotra, MD, PhD, MNAMS 
Executive summary American Journal of Kidney Diseases
Renal replacement therapy in Latin America
American Journal of Kidney Diseases
Soluble CD14 and Endotoxin Levels in Hemodialysis Patients: A Tale of 2 Molecules  Victor F. Seabra, MD, George Thomas, MD, MPH, Bertrand L. Jaber, MD,
Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton 
III. Treating dyslipidemias
Lipoprotein abnormalities in diabetic nephropathy
Clinical Practice Recommendations For Peritoneal Dialysis Adequacy
Maristela Böhlke, PhD  American Journal of Kidney Diseases 
American Journal of Kidney Diseases 
Clinical Practice Guidelines for Peritoneal Dialysis Adequacy
International Journal of Cardiology
Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.
Muscle Relaxant Use Among Hemodialysis Patients: Prevalence, Clinical Indications, and Adverse Outcomes  Diana Mina, Kirsten L. Johansen, Charles E. McCulloch,
Presentation transcript:

II. assessment of dyslipidemias   American Journal of Kidney Diseases  Volume 41, Pages S22-S38 (April 2003) DOI: 10.1016/S0272-6386(03)00120-3

Fig 5 Causes of death among period prevalent patients 1997–1999, treated with hemodialysis, peritoneal dialysis, or kidney transplantation. Data are from the USRDS 2001 Annual Data Report (www.usrds.org). Abbreviations: MI, myocardial infarction; HD, heart disease. American Journal of Kidney Diseases 2003 41, S22-S38DOI: (10.1016/S0272-6386(03)00120-3)

Fig 6 Example demonstrating the relative contributions of VLDL and IDL remnants to non-HDL cholesterol in two hypothetical patients with normal and high triglycerides, respectively. Although both patients A and B have the same total and HDL cholesterol levels, for patient A with normal triglycerides, most of the non-HDL cholesterol is LDL. However, for Patient B with high triglycerides, much of the non-HDL cholesterol is VLDL and IDL remnants. Units are in mg/dL. To convert mg/dL to mmol/L, multiply triglycerides by 0.01129 and total, LDL, HDL and non-HDL cholesterol by 0.02586. Abbreviations: VLDL, very low-density lipoproteins; IDL, intermediate density lipoproteins; LDL, low-density lipoproteins; HDL, high-density lipoproteins. American Journal of Kidney Diseases 2003 41, S22-S38DOI: (10.1016/S0272-6386(03)00120-3)